Characterization of α2-adrenoceptors mediating contraction of dog saphenous vein: Identity with the human α(2A) subtype

British Journal of Pharmacology

Volumn 121, Issue 8, 1997, Pages 1721-1729

  MacLennan, S J ^a   Luong, L A ^a   Jasper, J R ^a   To, Z P ^a   Eglen, R M ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

2 adrenoceptors; Dog saphenous vein; Human recombinant receptors; Operational model; Vascular smooth muscle

Indexed keywords

2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 5,6 DIHYDROXY 1 (2 IMIDAZOLIN 2 YL)TETRALIN; ALKYLATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; GUANABENZ; GUANFACINE; IDAZOXAN; IMIDAZOLINE; NORADRENALIN; OXYMETAZOLINE; PHENOXYBENZAMINE; PRAZOSIN; RADIOLIGAND; RAUWOLSCINE; RECEPTOR SUBTYPE; SPIROXATRINE; TOLAZOLINE;

ALKYLATION; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; FEMALE; HAMSTER; LIGAND BINDING; LUNG ALVEOLUS CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR AFFINITY; SAPHENOUS VEIN; SMOOTH MUSCLE CONTRACTION; SPECIES DIFFERENCE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CRICETINAE; DOGS; FEMALE; HUMANS; MALE; NOREPINEPHRINE; PHENOXYBENZAMINE; QUINOLIZINES; RECEPTORS, ADRENERGIC, ALPHA-2; SAPHENOUS VEIN; VASOCONSTRICTION; YOHIMBINE;

EID: 0030807197     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701296     Document Type: Article

References (46)

1. 2-Adrenoceptor blocking profile of SK&F 104078: Further evidence for receptor subtypes. Br. J. Pharmacol., 102, 943-949.
2. ALABASTER, V.A., KEIR, R.F. & PETERS, C.J. (1985). Comparison of activity of alpha-adrenoceptor agonists and antagonists in dog and rabbit saphenous vein. Naunyn-Schmiedeberg's Arch. Pharmacol., 330, 33-36.
3. ARUNLAKSHANA, O. & SCHILD, H.O. (1959). Some quantitative uses of drug antagonists. Br. J. Pharmacol., 14, 48-58.
4. BARLOW, R.B., SCOTT, N.C. & STEPHENSON, B.P. (1967). The affinity and efficacy of onium salts on frog rectus abdominis. Br. J. Pharmacol., 31, 188-196.
5. BLACK, J.W. & LEFF, P. (1983). Operational models of pharmacological agonism. Proc. R. Soc. Lond. B., 220, 141-162.
6. BLAYLOCK, N.A. & WILSON, V.G. (1995). Pharmacological characterisation of noradrenaline-induced contractions of the porcine isolated palmar lateral vein and palmar digital artery. Br. J. Pharmacol., 114, 694-702.
7. BROWN, M.J. (1989). Investigation of Alpha2-Adrenoceptors in humans. Am. J. Med., 87, (S3), 6S-9S.
8. 2-adrenergic receptors: Comparison of pharmacologically defined subtyes with subtypes identified by molecular cloning. Mol. Pharmacol., 42, 1-5.
9. BYLUND, D.B., EIKENBURG, D.C., HIEBLE, J.P., LANGER, S.Z., LEFKOWITZ, R.J., MINNEMAN, K.P., MOLINOFF, P.B., RUFFOLO, R.R. Jr. & TRENDELENBURG, U. (1994). IV. International Union of Pharmacology Nomenclature of Adrenoceptors. Pharmacol Rev., 46, 121-136.
10. BYLUND, D.B. & RAY-PRENGER, C. (1989). Alpha-2A and Alpha-2B adrenergic receptor subtypes: Attenuation of cyclic AMP production in cell lines containing only one receptor subtype. J. Pharmacol. Exp. Ther., 251, 640-644.
11. CHENG, Y.C. & PRUSOFF, W.H. (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (pIC50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
12. 2C-Adrenoceptors mediate norepinephrine-induced contraction of rat caudal artery. FASEB J., 9, A106.
13. 1-adrenoceptors in dog saphenous vein exposed to phenoxybenzamine. Eur. J. Pharmacol., 85, 325-329.
14. CULLEN, B.R. (1987). Use of eukaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol., 152, 684-704.
15. DALY, C.J., DUNN, W.R., MCGRATH, J.C. & WILSON, V.G. (1988). An attempt at selective protection from phenoxybenzamine of postjunctional α-adrenoceptor subtypes mediating contractions to noradrenaline in the rabbit isolated saphenous vein. Br. J. Pharmacol., 95, 501-511.
16. EISANACH, J.C. (1994). Alpha-2 agonists and analgesia. Exp. Opin. Invest. Drugs, 3, 1-6.
17. 2-adrenergic agonists. Anesthesiology, 74, 766-771.
18. FLAVAHAN, N.A., RIEMLE, T.J., COOK, J.P. & VANHOUTTE, P.M. (1984). Characterisation of postjunctional alpha-1 and alpha-2 adrenoceptors activated by exogenous or nerve-released norepinephrine in the canine saphenous vein. J. Pharmacol. Exp. Ther., 230, 699-705.
19. 2D-adrenoceptors modulating release of acetylcholine in guinea-pig ileum. Naunyn-Schmiedeberg's Arch. Pharmacol., 252, 58-66.
20. FURCHGOTT, R.F. (1996). The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In Advances In Drug Research. Vol. 3. ed. Harper, N.J. & Simmonds, A.B. pp. 283-335, London: Academic Press.
21. 2-adrenoceptor subtypes mediating vascular responses. Br. J. Pharmacol., 119, 89P.
22. HOYER, D. (1988). Functional correlates of serotonin 5-HT1 recognition sites. J. Receptor Res., 8, 59-81.
23. 2B-C2 expressed in sf9 cells couple to transduction pathway resulting in opposite effects on cAMP production. Eur. J. Pharmacol., 290, 75-83.
24. 35S]GTPγS binding. FASEB J., 10, N3, P2417.
25. 2-adrenergic receptor. J. Biol. Chem., 266, 10470-10478.
26. LEFF, P., PRENTICE, D.J., GILES, H., MARTIN, G.R. & WOOD, J. (1990). Estimation of agonist affinity and efficacy by direct, operational model fitting. J. Pharmacol. Methods, 23, 225-237.
27. 2A-autoreceptors in rabbit atria and kidney. Naunyn-Schmiedeberg's Arch. Pharmacol., 252, 31-42.
28. 2D-autoreceptors in mouse brain. Naunyn-Schmiedeberg's Arch. Pharmacol., 252, 43-48.
29. 2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol. Pharmacol., 42, 16-27.
30. 2-adrenergic receptor subtypes b and c. Science, 273, 803-805.
31. 2A subtype. FASEB J., 10,N3 P2334.
32. 2a-adrenergic receptor subtype. Science, 273, 801-803.
33. MCGRATH, J.C., BROWN, C.M. & WILSON, V.G. (1989). Alpha-Adrenoceptors: A critical review. Med. Res. Rev., 9, 407-533.
34. RAlpha-2A adrenergic receptors in the control of nociception, motor behavior and hippocampal synthesis of noradrenaline. J. Pharmacol. Exp. Ther., 270, 958-972.
35. 2-autoreceptors in the rabbit pulmonary artery and human saphenous vein. Naunyn-Schmiedeberg's Arch. Pharmacol., 252, 483-490.
36. ORIOWO, M.A., HIEBLE, J.P. & RUFFOLO, R.R. Jr. (1991). Evidence for heterogeneity of pre-junctional alpha-2-receptors. Pharmacology, 43, 1-13.
37. RUFFOLO, R.R. Jr., BONDINELL, W. & HIEBLE, J.P. (1995). α- and β-Adrenoceptors: From the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J. Med. Chem., 38, 3681-3716.
38. SHERMAN, S., LOOMIS, C., MILNE, B. & CERVENKO, F. (1987). Prolonged spinal analgesia in the rat with the α-adrenoceptor agonist oxymetazoline. Eur. J. Pharmacol., 140, 25-32.
39. 2-adrenoceptors in rat atrium, vas deferens and submandibular gland. Eur. J. Pharmacol., 211, 251-256.
40. 2D-subtype? Eur. J. Pharmacol., 219, 203-210.
41. STRUYKER BOUDIER, H., SMEETS, G., BROUWER, G. & VAN ROSSUM, J. (1974). Central and peripheral α-adrenergic activity of imidazoline derivatives. Life Sci., 15, 887-894.
42. SULLIVAN, A.T. & DREW, G.M. (1990). Pharmacological characterisation of pre- and postsynaptic α-adrenoceptors in dog saphenous vein. Naunyn-Schmiedeberg's Arch. Pharmacol., 314, 249-258.
43. 2C adrenoceptor subtypes. Biochem. Pharmacol., 51, 291-300.
44. 2D-autoreceptors in guinea-pig atria and brain. Naunyn-Schmiedeberg's Arch. Pharmacol., 252, 49-57.
45. 3H]-MK912 is Alpha-2C selective among human alpha-2A, alpha-2B, alpha-2C adrenoceptors. J. Pharmacol. Exp. Ther., 271, 1558-1565.
46. YAKSH, T.L. (1985). Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing. Pharmacol. Biochem. Behav., 22, 845-858.